We are live on ! Find out more
CNST

Constellation Pharmaceuticals, Inc.
CNST

Delisted

CNST was delisted on the 14th of July, 2021.

100 hedge funds and large institutions have $1.8B invested in Constellation Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,733% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 3

1,292% more capital invested

Capital invested by funds: $129M → $1.8B (+$1.67B)

300% more funds holding in top 10

Funds holding in top 10: 312 (+9)

229% more call options, than puts

Call options by funds: $2.65M | Put options by funds: $807K

117% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 12

108% more funds holding

Funds holding: 48100 (+52)

Holders
100
Holders Change
+52
Holders Change %
+108.33%
% of All Funds
1.97%
Holding in Top 10
12
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+300%
% of All Funds
0.24%
New
55
Increased
26
Reduced
12
Closed
3
Calls
$2.65M
Puts
$807K
Net Calls
+$1.84M
Net Calls Change
+$1.84M
Name Holding Trade Value Shares
Change
Change in
Stake
Invesco
26
Invesco
Georgia
$9.57M +$5.86M +203,143 New
ACP
27
Acuta Capital Partners
California
$9.3M +$5.7M +197,500 New
Northern Trust
28
Northern Trust
Illinois
$8.57M +$761K +26,345 +17%
BBA
29
Baker Bros. Advisors
New York
$6.28M
CS
30
Candriam SCA
Luxembourg
$5.83M +$3.57M +123,774 New
PAWC
31
P.A.W. Capital
Connecticut
$5.18M -$1.44M -50,000 -31%
LGM
32
Logos Global Management
California
$4.76M +$2.92M +101,050 New
CCM
33
Cadian Capital Management
New York
$4.54M +$2.78M +96,400 New
Renaissance Technologies
34
Renaissance Technologies
New York
$4.42M +$2.71M +93,779 New
Citadel Advisors
35
Citadel Advisors
Florida
$4.27M +$2.62M +90,630 New
SSA
36
Schonfeld Strategic Advisors
New York
$3.83M +$2.35M +81,300 New
N
37
Nuveen
North Carolina
$3.32M +$850K +29,426 +72%
AA
38
ALPS Advisors
Colorado
$3.18M +$465K +16,117 +31%
JRP
39
Jasper Ridge Partners
California
$2.9M
Two Sigma Investments
40
Two Sigma Investments
New York
$2.77M +$1.7M +58,835 New
PCM
41
Pinz Capital Management
New York
$2.77M +$1.69M +58,700 New
Bank of New York Mellon
42
Bank of New York Mellon
New York
$2.41M +$519K +17,985 +54%
EGI
43
EAM Global Investors
California
$2.17M +$1.33M +46,163 New
XSC
44
X-Square Capital
Puerto Rico
$2.06M +$1.26M +43,630 New
SCM
45
Soleus Capital Management
Connecticut
$1.98M +$1.22M +42,100 New
ARTA
46
A.R.T. Advisors
New York
$1.88M +$1.15M +39,984 New
Charles Schwab
47
Charles Schwab
California
$1.83M +$191K +6,602 +20%
Morgan Stanley
48
Morgan Stanley
New York
$1.74M +$899K +31,125 +534%
EI
49
EAM Investors
California
$1.68M +$1.03M +35,719 New
Dimensional Fund Advisors
50
Dimensional Fund Advisors
Texas
$1.65M +$1.01M +35,018 New

CNST Hedge Fund Activity: Q4 2019 in Review

100 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q4 2019, worth a combined $1.8B — up 1,292% from $129M a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new CNST positions and 3 closed out — a net gain of 52 holders — while 26 added to existing stakes and 12 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $105M. The largest seller was Regents of the University of California, cutting an estimated $15.9M.

  • 100 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q4 2019, up from 48 in Q3 2019.
  • Funds reported $1.8B of Constellation Pharmaceuticals, Inc. stock for Q4 2019, up 1,292% quarter-over-quarter.
  • 55 funds opened new Constellation Pharmaceuticals, Inc. positions in Q4 2019 and 3 closed out, a net change of +52 holders.
  • The largest Constellation Pharmaceuticals, Inc. buyer in Q4 2019 was Avoro Capital Advisors, an estimated $105M added.
  • The largest Constellation Pharmaceuticals, Inc. seller in Q4 2019 was Regents of the University of California, an estimated $15.9M sold.

Based on aggregated 13F filings for Q4 2019.